SCHEMBL8306977

SCHEMBL8306977

Cc1ccc(N2CCCOC2=O)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CCR1 P32246 1/20 0.37
CCR2 P41597 1/20 0.37
KCNQ2 O43526 1/20 0.36
PARP1 P09874 1/20 0.36
HSD17B10 Q99714 1/20 0.35
P2RX7 Q99572 2/20 0.34
ADCY2 Q08462 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
SRD5A1 P18405 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8305764 0.91 LMNA (0.41) LMNAALDH1A1HPGDSMN1; SMN2CCR1
SCHEMBL8306548 0.85 ALDH1A1 (0.43) LMNAALDH1A1HPGDHSD17B10P2RX7
SCHEMBL8306576 0.82 METAP2 (0.41) ALDH1A1SMN1; SMN2HSD17B10P2RX7SRD5A1
SCHEMBL29348998 0.82 LMNA (0.37) LMNAALDH1A1CCR1CCR2PARP1
SCHEMBL14547591 0.79 ALDH1A1 (0.36) ALDH1A1HPGDHSD17B10P2RX7
SCHEMBL10192200 0.79 PARP1 (0.47) LMNAALDH1A1HPGDSMN1; SMN2PARP1
SCHEMBL8306091 0.77 HSD17B10 (0.50) LMNAALDH1A1CCR1CCR2PARP1
SCHEMBL8305775 0.76 HSD17B10 (0.45) ALDH1A1CCR1CCR2KCNQ2PARP1
SCHEMBL12848677 0.75 HSD17B10 (0.44) ALDH1A1SMN1; SMN2CCR1CCR2PARP1
SCHEMBL8306520 0.75 ALDH1A1 (0.46) LMNAALDH1A1HPGDSMN1; SMN2CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed
WO-2004082687-A1 LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS F12, F2, PEPD LMNA 2107/4885ALDH1A1 3204/4885HPGD 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.